Sera Prognostics Inc

NASDAQ SERA

Data sourced from

and

Download Data

Sera Prognostics Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: -3.94

Sera Prognostics Inc Retained Earnings To Equity Ratio is -3.94 for the Trailing 12 Months (TTM) ending March 31, 2024, a -94.88% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders.

Sera Prognostics Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -2.02, a -214.39% change year over year.
Sera Prognostics Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.64, a -161.10% change year over year.
Sera Prognostics Inc Retained Earnings To Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 1.05.

NASDAQ: SERA

Sera Prognostics Inc

CEO	Dr. Gregory C. Critchfield M.D., M.S.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees	55
Sector	Healthcare
Industry	Diagnostics & research

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends